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Summary The effect of chemotherapy on the serum lipid mobilising activity of a group of cancer patients
with or without weight loss has been determined. The pre-treatment level of serum lipolytic activity in all
cancer patients, with or without weight loss, was higher than normal controls (0.22±0.01 versus 0.06+
0.01 jAmol glycerol released ml-' serum respectively). The pre-treatment levels of lipid mobilising activity in the
patients serum was proportional to the extent of weight loss (correlation coefficient 0.81), if the extent of
weight loss was small (<14 kg). Patients who showed a positive response to chemotherapy also showed a
decrease in their plasma levels of lipolytic activity, while a patient who showed no response to therapy also
showed no change in the serum lipolytic activity. There was no correlation between the serum lipolytic activity
and response to megestrol acetate, a synthetic orally active progestogen, which is currently under investigation
as an anticachectic agent. Serum from cancer patients showed lipolytic activity which was retained on a DEAE
cellulose column and eluted by a salt gradient, in contrast with normal controls. Response to chemotherapy
was associated with a decrease of the retained material, although the profile did not return to the normal state.
These results need confirmation in a larger group of patients using more specific methods to determine tumour
lipolytic activity, but suggest that it may be possible to monitor response to therapy by measurement of the
serum lipolytic activity.
Loss of body fat accounts for the major portion of weight
loss in cancer patients (Heymsfield & McManus, 1985), and
an increased rate of lipolysis appears to precede progressive
loss of skeletal muscle in sarcoma-bearing rats (Ekman et al.,
1982). Several factors have been postulated to account for an
increased lipid mobilisation in the tumour-bearing state.
These can be divided into direct lipid mobilising factors such
as toxohormone L (Masuno et al., 1981), a serum factor
produced by a thymic lymphoma in AKR mice (Kitada et
al., 1980, 1981) and a serum factor produced by a cachexia-
inducing murine colonic tumour (MAC16) (Beck & Tisdale,
1987), and indirect factors such as tumour necrosis factor
(TNF), which is thought to stimulate breakdown of adipose
tissue as a result of the inhibition of the enzyme lipoprotein
lipase, thus blocking synthesis of triglycerides (Oliff, 1988).
Using chromatographic characterisation we have recently
shown that the lipid mobilising factor found in the serum
and urine of animals bearing the MAC16 tumour is also
present in the serum and urine of humans with clinical cancer
cachexia (Beck & Tisdale, in preparation). In cancer patients
the level of this factor appears to correlate directly with the
extent of weight loss, although even patients without weight
loss have significantly elevated serum lipolytic activity when
compared with non-cancer controls. This suggests that the
lipid mobilising factor may be related to the tumour-bearing
state and that alteration in the level may occur in response to
therapy. If this is correct it could provide an alternative
measurement of the response of tumours to therapy. The
present report documents the effect of therapy on the serum
lipolytic activity of a diverse group of cancer patients, with
and without weight loss, at the time of initiation of treat-
ment.
Materials and methods
Subjects
Thirteen patients, seven male and six female with histo-
logically proven malignancy and various degrees of weight
loss were entered into the study (Table I). Eight of the
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patients received chemotherapy or radiotherapy with curative
intent, while five patients with advanced unresponsive
tumours were given megestrol acetate (320-1600 mg m 2) in
an attempt to control their weight loss. Weight loss was
calculated from the pre-morbid weight. Serum samples were
taken prior to treatment, during and, if possible, after treat-
ment and were taken in the fed state. Blood samples were
allowed to clot on ice for 60 min, centrifuged and the serum
separated. The samples were stored at - 70C until assay and
were not used after re-freezing. Serum samples from patients
with Alzheimer's disease and weight loss of unknown cause
were kindly provided by Dr I.N. Ferrier, MRC Neurochem-
ical Pathology Unit, Newcastle upon Tyne. Food intake and
appetite scores were determined by the patient using two
scores. In the first the patient ticks a number from 1 to 5
where 1 = much less than usual and 5 = much more than
usual. The second determination was from a 10cm linear
analogue scale where 0 = no intake and 10 = much more
than normal.
Chromatographic characterization
Serum samples (1 ml) were fractionated by anion exchange
chromatography using a DEAE cellulose column (dimensions
1.6 x 30 cm) equilibrated with 10 mM phosphate, pH 8.0.
Active material was eluted from the column using a linear
gradient of 0.08-0.2 M NaCl in 10 mM phosphate, pH 8.0.
The column was eluted at a flow rate of 30 ml h-' and the
effluent was assayed for lipolytic activity.
Determination oflipolytic activity
Mice (strain BKW) were killed by cervical dislocation and
their epididymal adipose tissue was removed and placed in
isotonic saline, minced and incubated at 37°C for 2 h in
Krebs Ringer bicarbonate buffer, pH 7.2, containing 2mg
ml-' of collagenase (Sigma Chemical Co., Dorset, UK) with
prior gassing with 95% 02:5% C02. Digestion of the tissues
was detected by the disappearance of intact pieces and an
increased turbidity of the medium. Undigested material and
non-adipose matter was removed by allowing the fat cells to
float to the surface of the buffer and the infranatant was
aspirated and replaced with fresh buffer. The washing proce-
dure was repeated three times to remove all collagenase,
non-adipose cells and any endogenous hormones. After the
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Table I Characteristics of patients used in the study
Patient Sex Diagnosis Therap/a Responseb
1 F High grade lymphoma Cy,A,P,Vc,M,E CR
2 M High grade lymphoma Cy,A,Vc,P,M PR
3 M Malignant teratoma C,V,B,A,Cy,E CRC
4 M Hodgkin's disease CL,VB,PC,P,A,B,V,E NC
5 M Lymphomad Cy,A,P,Vc,M,E, CR
6 M Malignant teratoma C,Vc,B,A,Cy,E PR
7 F Cervical carcinoma Radiotherapy PR
8 F Cervical carcinoma Radiotherapy PR
9 F Cervical carcinoma Megace PD
10 F Breast carcinoma Megace PD
11 M Renal cell carcinoma Megace PD
12 M Lung carcinoma (squamous) Megace PD
13 F Colon carcinoma Megace PD
aCy = cyclophosphamide, A =adriamycin, P = prednisolone, Vc =vincristine, VB =
vinblastine, M = methotrexate, E = etoposide, C = cisplatinum, CL = chlorambucil,
B = bleomycin, Pc = Procarbazine, Megace = megestrol acetate. bCR = complete res-
ponse, PR = partial response, NC = no change, PD = progressive disease. cThere was
residual disease on CT scan thought to be benign teratoma. dLow grade relapsed - high
grade.
final wash the cells were suspended in an appropriate amount
of Krebs Ringer solution to give a density of 1.5 x 105
adipocytes ml-'; the cell number being enumerated with a
Neubauer haemocytometer.
Cell samples (1 ml) were removed, with continuous mixing
to maintain a homogeneous cell suspension, added to the
appropriate test substance, gassed with 95% 02:5% CO2 and
incubated for 2 h at 37°C in a shaking water bath. Control
samples containing adipocytes alone were also analysed to
measure any spontaneous glycerol release. When assaying
serum samples, a control (no adipocytes) was also included
to measure the initial amount of glycerol present in the
serum. Routinely samples of serum (100yl) were assayed in
duplicate and the assay was repeated 4-5 times on each
sample at different times. At the end of the incubation period
0.5 ml of the incubation buffer was added to 0.5 ml of 10%
(w/v) perchloric acid and the mixture was shaken to ensure
deproteinisation. The precipitated protein was sedimented by
centrifugation at 2,000 r.p.m. for 10 min, the supernatant
removed and neutralised with 20% (w/v) KOH, after which
the potassium perchlorate was sedimented by centrifugation
(2,000 r.p.m., 10min) and the volume of the supernatant was
recorded and used to calculate the dilution factor. Assays on
the supernatant were performed either immediately, or after
storage at - 20°C for between 18 and 72 h. The concentra-
tion of glycerol was determined enzymatically on 200 gl ali-
quots of the supernatant by the method of Wieland (1974).
The results are expressed as tsmol glycerol released ml' of
serum per I05 adipocytes, minus both the fat cell control
value and the serum control value.
Statistical analysis
Results are expressed as mean ± s.e.m. for at least five
separate determinations performed in duplicate on a single
patient when samples were available. Differences were deter-
mined statistically using Student's t test.
Results
The characteristics of the patients employed in this study is
given in Table I and the serum lipolytic activity before and
after treatment is shown in Table II. The pre-treatment levels
of serum lipolytic activity in all patients with or without
weight loss were higher than normal controls (0.22 ± 0.01
versus 0.06 ± 0.01 jsmol glycerol released ml-' serum respec-
tively) or patients with Alzheimer's disease and weight loss
(0.11 ± 0.021tmol glycerol released ml' serum (P<0.001)).
The pre-treatment levels of serum lipolytic activity increase as
the weight loss increases for patients with weight loss up to
14 kg (Figure 1, r = 0.81) but do not correlate with higher
weight loss.
The patients can be divided into two groups according to
the type of treatment. Patients 1 to 8 (Table II) were given
either radiotherapy or chemotherapy with curative intent,
while patients 10 to 13 had advanced unresponsive tumours
and significant weight loss, and were given symptomatic
treatment with megestrol acetate (320-1,600 mg m-2) to con-
trol weight loss as part of an ongoing clinical trial. Patients
1, 2, 3, 5, 7 and 8 showed a significant decrease in the plasma
levels of lipolytic activity, either during or after treatment,
and all showed a response to antitumour therapy. Post-
treatment serum levels of lipolytic activity in patients 1 and 2
and values for 1 and 7 during treatment were not signi-
ficantly different from normal controls.
In contrast, patient 4 showed no alteration in serum
lipolytic activity either during or after treatment and showed
no response to chemotherapy. Only patient 6 showed an
alteration in serum lipolytic activity opposite to that expected
from the tumour response to therapy. Thus, although there
was a marked clinical response to treatment, the serum
lipolytic activity apparently increased. This patient was also
receiving warfarin (4-5 mg day-') which may have interfered
with the lipolytic assay. In separate experiments, we have
shown warfarin to markedly increase the apparent glycerol
concentration using the coupled enzyme assay (Wieland,
1974), especially at low concentrations of glycerol. If this
value is excluded the average serum value of lipolytic activity
after treatment (0.10 ± 0.02timol glycerol released ml-') was
significantly (P<0.05) lower than the pre-treatment serum
level (0.21 ± 0.03gmol glycerol release ml') for those
patients who responded to chemotherapy.
None of the patients given the high dose megestrol acetate
exhibited a decreased tumour burden, although patients 9
and 10 did respond symptomatically with a marked increase
in appetite and body weight. However, only patient 9 showed
unequivocal weight gain, since weight gain in patient 10 was
associated with a pleural effusion. All patients except patient
11 increased their food intake in response to megestrol
acetate treatment. Patients 11, 12 and 13 showed either no
response or progression of their weight loss while receiving
megestrol acetate. Serum lipolytic activity was decreased in
patients 10 and 12 after treatment with megestrol acetate.
In order to investigate the molecular species responsible for
the lipid mobilising activity in the serum of cancer patients
and the effect of therapy on activity, we have subjected the
serum of a large number of cancer patients and controls to
DEAE cellulose chromatography with a salt gradient from
0.08 to 0.2 M NaCl and a representative chromatogram for
patient 3 was compared with a representative profile obtained
with serum from a normal subject (Figure 2). Most of the
serum lipid mobilising activity in normal subjects was not
retained by a DEAE cellulose column and appeared as a
single peak at the start of the salt gradient (Figure 2c). In
contrast, serum from the cachectic patients, in addition to an824 S.A. BECK et al.
Table II Effect of therapy on serum lipolytic activity
Serwn lipolytic activity smolglycerol m' Weight change
Weight loss during therapy
Patient (kg) Pre-treatment During treatment Post-treatment (kg)
1 2 0.20±0.1 0.10_0.01ef 0.11±O.Old,f -5.1
2 0 0.26±0.04 0.24±0.01 O.Il±O.Old +1.8
3 5 0.22±0.04 0.13±o.Old 0.17±0.01 -7.5
4 0 0.16±0.01 0.14±0.02 - -7.5
5 7 0.33±0.02 0.14±0.01 0.14±0.001
6 2.6 0.12±0.006 0.40±0.01 - -1.4
7 0 0.14±0.02 0.02±0.01 - + 1.1
8 5.8 0.10±0.02 0.05±0.02 - +4.0
9 3.4 0.11±0.006 0.13±0.01 - +5.2
10 14 0.63a 0.18±0.01 - +6.9
11 2.3 0.12±0.02 0.08±0.01 0.095±0.01 -3.7
12 11.7 0.36±0.03ef 0.11±0.03 - 0
13 24 0.12±0.01 0.07±0.02 - 0
Controlb 14±3 0.11±0.02 -
Controlc 0 0.06±0.01
aInsufficient sample formultiple determinations to be made. bSerum was obtained from ten patients with
Alzheimer's disease. cSerum wasobtained from six normal subjects. dp<0.05 from pre-treatment values by
Student's t test. CP<0.01 from pre-treatment values by Student's t test. 'Value not significantly different
from control subjects.
Cancer patients with or without weight loss have been
shown to have a higher serum level oflipid mobilising factors
.R = 0.81 than normal subjects or patients with Alzheimer's disease and
weight loss. We have carried out an extensive number of
'1/ chromatographic analyses of serum from cachectic cancer
patients and normal subjects (Beck, 1989) and in all cases
this material has different chromatographic characteristics
from the lipid mobilising activity found in the serum of
normal controls. Retention of such material by DEAE cellu-
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Figure 1 Relationship between serum lipolytic activity of a
group of cancer patients before treatment and weight loss. The
lipolytic activity is expressed as jsmol glycerol released per 101
adipocytes in a 2 h incubation per ml serum.
increased total lipid mobilising activity, contained peaks of
activity retained by the DEAE cellulose and eluted by the
salt gradient. These peaks of lipolytic activity, which appear
specific to the cancer cachectic state, and eluting between 0.1
and 0.15 M NaCl were reduced in activity by approximately
40% in response to chemotherapy. However, although the
patient had an almost complete response to the therapy there
was still an indication that peaks specific to the neoplastic
state were present (Figure 2b).
Many factors are involved in the progressive wasting of
neoplastic diseases. These include metabolic abnormalities
and anorexia as well as treatment toxicity, which may lead to
learned food aversions. However, cachexia may also be
mediated by tumour products which act to degrade host
body tissues contributing to the wasting process. The rela-
tionship of such products to tumour growth and status has
not previously been determined. However, we have been able
to correlate weight loss in animals bearing an experimental
cachexia-inducing tumour with the presence in the serum and
tumour of material capable of inducing lipolysis in murine
adipocytes (Beck & Tisdale, 1987). We have now applied this
same assay to monitor the level of lipid mobilising activity in
the serum of cancer patients and the effect of therapy on
activity.
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Figure 2 DEAE cellulose chromatography of serum from
patient 3 before treatment (a) and during treatment (b) and from
a normal subject (c). The lipolytic activity is expressed as psmol
glycerol released per 101 adipocytes in a 2h incubation.
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lose would indicate that the material has a negative charge,
in contrast with the normal lipolytic hormones, which are all
positively charged. Patients with weight loss have a higher
serum level of lipolytic activity than non-weight losing
patients, which correlates positively with the extent of weight
loss if the percentage loss of carcass weight does not exceed
20%. A similar, non-linear correlation between serum lipo-
lytic activity and weight loss has been observed in animals
bearing the MAC16 tumour, an experimental model of
cancer cachexia (Beck & Tisdale, 1987). Here serum lipolytic
activity increases with weight loss until the total loss of
carcass weight reaches 16% and thereafter decreases with
increasing weight loss. The reason for this decrease in serum
lipolytic activity with large weight loss is not known.
The function of such a material in tumour growth and
weight loss must await its purification and indentification.
However, the presence of this material may provide an
independent assay system for determining the response of
cancer patients to various treatment regimes, and in the
present study we have attempted to correlate serum levels
with response to therapy. Although we have only utilised
serum values in the present study the technique would also
be applicable to urine, especially when a more sensitive
bioassay system becomes available. Problems arise in the
routine detection of lipolytic activity in urine when the urine
volume is large, and the concentration of lipolytic factor is
below the level ofdetection in the present bioassay system, or
where kidney function is impaired. In order to obtain consis-
tent results with serum it is important that repeat determina-
tions are not done with refrozen specimens.
For patients with various types of tumours receiving
chemotherapy or radiotherapy the concentration of serum
lipid mobilising factors in general decreased in response to
effective therapy. The single exception was a patient with a
malignant teratoma, who was also receiving warfarin, which
was subsequently shown to interfere with the bioassay. For
the other patients the average serum lipolytic activity
decreased from 0.21 ± 0.03 to 0.10 ± 0.02 ymol glycerol
released ml' (P<0.05) where a response was obtained. A
potential problem in the measurement of serum lipolytic
activity in patients receiving chemotherapy is the possibility
of drug interference in the bioassay. However, confirmation
that a specific effect has been obtained can be determined by
ion exchange chromatography of the serum before and after
treatment. Where a clinical response is observed this is
associated with a decrease in the lipid mobilising activity
retained by a DEAE cellulose column, although the profile
does not return to the normal state.
Megestrol acetate is a synthetic, orally active progestogen,
widely used for the therapy of advanced breast cancer.
Recently this agent has been shown to produce weight gain
in more than 80% of all treated patients, with a subjective
improvement in appetite occurring in most patients (Aisner et
al., 1988), and is currently being evaluated for the control of
cachexia in cancer. Of the five evaluable patients receiving
megestrol acetate two showed a marked increase in body
weight accompanied by an increase in both appetite and food
intake although only one showed unequivocal weight gain.
There was no reduction in tumour mass in either patient and
there was definite tumour progression and both died soon
after. However, the serum lipolytic activity was significantly
reduced in one patient (patient 10). Patient 12 also responded
to megestrol acetate with an increase in both appetite and
food intake, and although there was no alteration in body
weight the serum lipolytic activity was also reduced. The only
two patients to show a decrease in serum lipolytic activity
with megestrol acetate had high initial values and these
patients also had the most marked increase in appetite and
food intake. Thus, there seems to be no simple relationship
between change in serum lipolytic activity and response to
megestrol acetate, although there may be a correlation with
food intake. The role of the lipolytic factor and its specificity
for the neoplastic state awaits further characterisation.
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